View Post

Data Presented at ESMO Provides Rationale for Clinical Trial of Onvansertib in Subset of Patients with Highly-Aggressive Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: prnewswire.com – Significant tumor regression observed with onvansertib in combination with standard-of-care paclitaxel in models of p53-mutated TNBC – Onvansertib preclinical data provides rationale for clinical trial targeting the 80% of TNBC that harbors the p53 mutation – Combination has potential to address critical medical need to provide targeted treatment option to overcome resistance to paclitaxel as single agent …

View Post

Immunotherapy Active in Early Stage Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Liam Davenport From: medscape.com New hope for patients with triple negative breast cancer (TNBC) has been raised with results showing that immunotherapy has activity in early stage disease, after they were raised last year — and then subsequently dashed — by results with immunotherapy in the metastatic setting. TNBC accounts for 15% of breast cancer cases, but unlike other …

View Post

Triple-Negative Breast Cancer Classification From Whole-Genome Sequencing Can Inform Treatment

In In The News by Barbara Jacoby

By: Staff Reporter From: genomeweb.com Whole-genome sequencing could help to further categorize triple-negative breast cancers into groups that may respond to different treatment approaches, according to a new study. An international team of researchers sequenced 254 triple-negative breast cancer tumors from patients from the Sweden Cancerome Analysis Network-Breast (SCAN-B) project, an ongoing population-based observational study of breast cancer patients in …

View Post

New SU2C teams accelerate clinical trials for difficult breast & prostate cancers

In Clinical Trials by Barbara Jacoby

Source: Stand Up To Cancer From: eurekalert.org Stand Up To Cancer (SU2C) is launching teams of experts to lead innovative attacks on two types of cancer that have defied conventional treatment: triple-negative breast cancer (TNBC) in women and metastatic prostate cancer in men. The $6 million effort supported by SU2C Catalyst Founding Collaborator, Genentech, a member of the Roche Group, …

View Post

Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: biospace.com Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC), which is currently considered an incurable cancer with limited therapeutic options. Genprex has no affiliation with these …

View Post

Preclinical study reveals the impact of age on immunotherapy treatment for breast cancer

In Clinical Trials by Barbara Jacoby

Source: Brigham and Women’s Hospital From: eurekalert.org Recent clinical trials have indicated that immune checkpoint blockade (ICB) therapy, which is designed to unleash a patient’s immune system to attack cancer, has been revolutionary in its implications for breast cancer treatment, especially for its potential to treat patients with triple negative breast cancer (TNBC). Despite the fact that most breast cancer …

View Post

Diverse immune cell profiles and roles found in breast cancer resistance to immunotherapy

In In The News by Barbara Jacoby

Source: Baylor College of Medicine From: sciencedaily.com Researchers show that heterogeneity of both breast cancer cells themselves and immune composition of the tumor microenvironment are important considerations for therapy.  In recent years it has been increasingly appreciated that immune cells within the tumor microenvironment contribute to tumor progression and, importantly, to the tumor’s response to therapy. To better understand the …

View Post

CRISPR gene editing may halt progression of triple-negative breast cancer

In In The News by Barbara Jacoby

Source: Boston Children’s Hospital From: eurekalert.org A tumor-targeted CRISPR gene editing system, encapsulated in a nanogel and injected into the body, could effectively and safely halt the growth of triple-negative breast cancer, report researchers at Boston Children’s Hospital. Their proof-of-principle study, conducted in human tumor cells and in mice, suggests a potential genetic treatment for triple-negative breast cancer, which has …

View Post

Patient Treated with Leronlimab (PRO 140) for Metastatic Triple-Negative Breast Cancer under Emergency IND, Launching CytoDyn into Oncology

In Clinical Trials by Barbara Jacoby

Source: CytoDyn Inc. From: globenewswire.com CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the injection of the first patient with metastatic triple-negative breast cancer (“mTNBC”).  The patient will be treated with leronlimab by Jacob Lalezari, M.D., currently Chief Executive …

View Post

Keytruda Plus Chemo Shows High Response Rate in Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: specialtypharmacytimes.com Pembrolizumab (Keytruda, Merck) plus chemotherapy demonstrated a statistically significant improvement in pathological complete response rate (pCR) as a neoadjuvant therapy in patients with triple-negative breast cancer (TNBC), according to new data from a phase 3 study. Approximately 15% to 20% of patients with breast cancer are diagnosed with TNBC, which can be more difficult to treat than other …